Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ
Labcorp宣佈美國食品藥品管理局批准其nabCyte抗AAVRH74VAR HB-FE試驗(一種伴隨診斷),以確定患者是否有資格接受BEQVEZ治療,此後,Labcorp股價上漲